Treatment of Cutaneous and Lymphocutaneous Sporotrichosis
Clinical Scenario
This protocol applies to patients presenting with cutaneous sporotrichosis or lymphocutaneous sporotrichosis — two distinct clinical forms of this fungal infection addressed under the same evidence-based treatment framework.
Treatment Approach
Management of cutaneous and lymphocutaneous sporotrichosis involves an oral antifungal agent selected based on patient tolerability. Treatment is continued for an extended period to ensure complete resolution.
Full agent selection criteria, sequencing, and duration are in the structured protocol below.
References
DOI: 10.1086/522765
- For cutaneous and lymphocutaneous sporotrichosis, itraconazole (200 mg orally daily) is recommended to be given for 2–4 weeks after all lesions have resolved, usually a total of 3–6 months (A-II).
- Fluconazole at a dosage of 400–800 mg daily should be used only if the patient cannot tolerate other agents (B-II).
View source ↗